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Simplified flow cytometric assay to detect minimal residual disease in childhood
with acute lymphoblastic leukemia
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The detection of minimal residual disease (MRD) is an important prognostic factor in
childhood acute lymphoblastic leukemia (ALL) providing crucial information on the
response to treatment and risk of relapse. However, the high cost of these techniques
restricts their use in countries with limited resources. Thus, we prospectively studied the
use of flow cytometry (FC) with a simplified 3-color assay and a limited antibody panel
to detect MRD in the bone marrow (BM) and peripheral blood (PB) of children with
ALL. BM and PB samples from 40 children with ALL were analyzed on days (d) 14 and
28 during induction and in weeks 24-30 of maintenance therapy. Detectable MRD was
defined as ≥ 0.01% cells expressing the aberrant immunophenotype as characterized at
diagnosis among total events in the sample. A total of 87% of the patients had an
aberrant immunophenotype at diagnosis. On d14, 56% of the BM and 43% of the PB
samples had detectable MRD. On d28, this decreased to 45% and 31%, respectively.
The percentage of cells with the aberrant phenotype was similar in both BM and PB in
T-ALL but about 10 times higher in the BM of patients with B-cell-precursor ALL.
Moreover, MRD was detected in the BM of patients in complete morphological remission
(44% on d14 and 39% on d28). MRD was not significantly associated to gender, age,
initial white blood cell count or cell lineage. This FC assay is feasible, affordable and
readily applicable to detect MRD in centers with limited resources. Rev. bras. hematol.
hemoter. 2008;30(4):281-286.
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Introduction
Early treatment response is an independent prognostic
factor in childhood acute lymphoblastic leukemia (ALL) and
exceedingly important to confirm the patient's risk group and
to define treatment intensity.1,2 The rate of clearance of
leukemic cells from the peripheral blood (PB) and bone marrow
(BM) can be measured by morphologic criteria, e.g., the
number of circulating lymphoblasts after one week of
chemotherapy,3,4 or the number of blasts in the BM during or
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at the end of induction therapy.5,6 Despite clinical usefulness,
measurements of residual leukemia by morphologic analysis
can be insensitive and imprecise. Patients who achieve com-
plete morphological remission may still have a high tumor
burden and, therefore, a high risk of relapse. Minimal residu-
al disease (MRD), as assessed by more sensitive and precise
methods, has emerged as a powerful prognostic indicator in
childhood ALL and has recently been incorporated in many
treatment protocols to identify the risk of relapse and to de-
fine therapeutic strategies.7-12
Several techniques have been developed over the past
10 to 15 years that go beyond morphology in assessing
response to treatment. In ALL, the most reliable methods for
MRD detection are polymerase chain reaction (PCR), to detect
fusion gene transcripts,13 rearranged immunoglobulin (Ig) and
T-cell receptor genes,14,15 and the detection of aberrant
immunophenotypes by flow cytometry (FC).8,9,16,17 Both
techniques can detect one leukemic cell or more in every
10,000 normal BM or PB cells. Choosing a specific technique
depends on the desired sensitivity and the applicability of
the technique to accomplish each specific clinical
objective.12,18 When optimally performed, molecular studies
are more sensitive, and may require fewer tumor cells in the
sample. FC is usually less expensive and faster than molecular
methods.19-21
Leukemia-associated immunophenotypes, used to
gauge MRD by FC, are usually absent in normal
hematopoiesis. These aberrant phenotypes usually involve
cross-lineage antigen expression (i.e., the expression of
myeloid markers in lymphoid blasts), maturational
asynchronous expression (co-expression of two or more
antigens that are not simultaneous in normal differentiation),
over- or under-expression, or ectopic antigen expression (the
presence of a marker that would be normal if the cell was in
another homing area).7,8,16,17
One of the greatest obstacles to perform FC is the high
initial cost and, in Brazil, the need to import all reagents.
Nonetheless, at least in most centers, a single-laser flow
cytometer is already available to diagnose childhood ALL.
Thus, we conducted a prospective single center study to
evaluate MRD in the BM and PB of children with ALL using
a 3-color FC assay with a limited antibody panel that is
reproducible in other centers and countries with limited
resources.
Patients and Method
From March 2003 to October 2004, 40 children with newly
diagnosed ALL admitted for treatment at our institution were
eligible for the present study. Diagnosis was based on the
criteria of morphological classification proposed by FAB and
on immunophenotyping with monoclonal antibodies. Patients
were from 0.4 to16 years old (median 5 years) with 23 boys
and 17 girls. Seven had T-lineage ALL (T-ALL) and 33 had
B-cell-precursor ALL (BCP-ALL). The children were treated
according to the guidelines of the Brazilian Cooperative Group
for the Treatment of Childhood Leukemia (GBTLI-LLA/99)
protocol (n=30) or the ALL Berlin-Frankfurt-Munster (BFM)-
95 protocol (n=10). This study was approved by the University
Ethics Committee and informed consent was obtained from
all parents or guardians.
BM and PB samples were obtained at diagnosis to
identify the leukemia-associated immunophenotypes and
during induction on days 14/15 (d14) and days 28/33 (d28)
and in weeks 24 to 30 of maintenance therapy to evaluate
MRD. Samples were collected in EDTAK3 and processed within
24 hours. MRD was determined in the BM and PB in 212
follow-up samples (112 BM and 100 PB). MRD studies were
only performed in samples with more than 1,000 leukocytes/
mm3. BM morphology was analysed at the same time points.
Immunophenotyping at diagnosis
Leukemic blasts were immunophenotyped using a two
or three color combination of monoclonal antibodies
conjugated to fluorescein isothiocyanate (FITC), phyco-
erythrin (PE), peridinin chlorophyll protein (PerCp) or
CyChrome: IgG1-FITC/PE/CyChrome; CD1a-FITC; CD2-PE;
CD3-PE/CyChrome; CD4-FITC; CD7-PE; CD8-PE; CD10-PE;
CD15-FITC; CD19-FITC/CyChrome; CD20-FITC; CD33-FITC/
PE; CD45-FITC; CD79a-PE (Becton Dickinson - Pharmingen,
San Jose, CA); CD10-FITC; CD22-PE; CD34-FITC/PE; CD45-
PerCp; MPO-FITC; terminal deoxynucleotidyl transferase
(TdT)-FITC (Becton Dickinson Biosciences, San Jose, CA);
CD13-PE; IgM-FITC (Dako, Carpinteria, CA). The stain and
lyse/wash technique was used, as previously reported.22
Data acquisition was performed using a FACSCalibur flow
cytometer (Becton Dickinson, San Jose, CA) equipped with
the Cell Quest computer program. A total of 15 x 103 non-
gated events were acquired. At least one useful aberrant
marker combination was identified at diagnosis and then used
to monitor MRD in the follow-up samples.
MRD evaluation
Matched non-reactive fluorochrome-conjugated
antibodies and the CD4-FITC/CD8-PE/CD3-CyChrome
combination were used as negative and positive controls,
respectively. A two-step acquisition procedure was applied.
In the first step, a total of 15 x 103 non-gated events were
acquired. In the second step, a live gate (LG) based on the
lineage marker expression was set: CD19 for BCP-ALL and
cytoplasmic (cy) CD3 for T-ALL, using low/ intermediate side
scatter characteristics (SSC - lymphoid scatter). The total
numbers of cells, usually 105-106 events passing though the
flow cytometer were recorded for each LG acquisition.22-25
The expression of all markers was analyzed within
CD19+ or cyCD3+/ lymphocyte SSC gate to determine the
presence of any cell subset with the aberrant marker.22-25 In
patients with no aberrant marker, MRD was monitored by
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triple-stainings: CD45/CD10/CD19; CD34/CD22/CD19; CD20/
CD10/CD19.23,24 Data analysis was achieved with the Paint-
a-Gate Pro software (Becton Dickinson, San Jose, CA). A
cluster of at least 10-20 events with the patients' aberrant
marker expression and adequate SSC was considered as MRD.
"Detectable MRD" was defined as the expression of the
leukemia-associated immunophenotype in 0.01% or more of
the total events present in the sample.22
Statistical analysis
Differences in the distribution of presented clinical and
biological features according to the existence of MRD in the
BM during induction were compared by Fisher's exact test.
Cohen's kappa was used as a measurement of agreement
between MRD in BM and PB. The Spearman's correlation
coefficient (rs) was determined to compare MRD levels in
paired BM-PB samples. For this analysis, only paired BM-PB
samples with detectable MRD in at least one sample were
included. The P-values were always two-tailed and values <
0.05 were regarded as statistically significant. The Statistical
Package for Social Science (SPSS) version 10.0 was used for
statistical calculations.
Results
In this study, 35 of the 40 patients (87%) had leukemia-
associated immunophenotypes suitable for MRD studies
by FC (Table 1). Most patients with BCP-ALL had at least
one aberrant marker (28/33 - 85%), with 20 (61%) having
two or more. All seven patients with T-ALL had suitable
phenotypes, based on the simultaneous detection of nu-
clear TdT and cyCD3. One T-ALL patient also had aberrant
myeloid markers.
 MRD results and association with clinical risk factors
About half of the patients had detectable MRD  in the
BM on d14 (20/36 - 56%) and on d28 (18/40 - 45%) but only
3% in weeks 24-30. At the end of induction (d28), MRD levels
were 0.01-0.1% in 11 patients (27.5%), 0.1%-1% in 2 (5%) and
≥ 1% in 5 (12.5%). For the remaining 22 patients (55%),
leukemic cells were below the detection threshold using this
technique (<0.01%). The presence of detectable MRD (MRD+)
in the BM during induction was not significantly associated
to gender, age, white blood cell count or cell lineage in this
limited number of patients (Table 2).
Correlation between MRD and BM morphology
Of the 112 follow-up BM samples studied by FC during
ALL therapy, 13 (12%) had ≥ 5% blasts identifiable by
morphology. In all of these samples, leukemic cells were also
identified by FC varying from 0.8% to 78% of the BM cells
(median, 25%). Among the 99 (88%) samples in complete
morphological remission (< 5% blasts), 73 (74%) had no
detectable cells expressing leukemia-associated immuno-
phenotypes. However, 26/99 (26%), remained MRD+ ranging
from 0.01-10.5% (median: 0.03%).
 MRD in the BM vs. PB
Of the 112 follow-up BM samples, 100 had
paired PB available for analysis. Twelve PB samples
could not be analyzed due to leukopenia. Eight of
the corresponding BM samples were MRD+ and
four had no detectable MRD.
A total of 39 BM samples (35%) had more
than 0.01% leukemic cells (0.01-78%; median 0.14%).
Thirty-one matched PB samples were available: 23
(74%) had ≥ 0.01% circulating blasts, whereas eight
(26%) had none (< 0.01%). In the 23 MRD+ PB
samples, levels ranged from 0.01% to 32% (median
0.045%). No detectable MRD was observed in the
remaining 69 BM-PB paired samples.
During induction, MRD measurements were
similar in the BM and PB. Of the 28 patients with
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paired BM and PB samples on d14, half had detectable MRD.
In two of these 28 patients (14%), MRD was detected only
in the BM (kappa 0.857, P<0.001). On d28, at the end of the
induction, 36 patients were evaluated and 16 (44%) had
positive samples. Of these, five were positive only for the
BM (kappa 0.710, P<0.001). Only one patient had detectable
MRD in the BM in weeks 24-30.
T-ALL patients had similar levels of MRD+ in the BM
and in the PB at all time points. The Spearman's correlation
coefficient (rs) was 1.0 (P<0.05) on d14 and 0.984 (P<0.001) on
d28. Therefore, in T-ALL, the PB reflected the BM MRD while
in BCP-ALL, MRD was more prevalent and present at higher
levels in the BM than in the PB (Figure 1). The Spearman's
correlation of PB and BM MRD was strong in BCP-ALL on
d14 (rs=0.892; P<0.001) and on d28 (rs=0.776, P<0.001),
although the MRD levels in the PB were usually lower than
in the paired BM samples.
Discussion
The morphologic detection of leukemic cells during
therapy is an important prognostic factor. However, it is
difficult to distinguish leukemic blasts from early lymphocytes
and undifferentiated normal hematopoietic cells only by
morphology. FC has the potential of overcoming these
limitations.7-9 In our study we showed that 44% (d14) and
39% (d28) of patients with morphologically normal BM during
induction actually had measurable MRD.
Sequential monitoring of MRD during the first months
of therapy provides information on the response to treatment
and has already been proved to be a powerful and
independent indicator of outcome in childhood ALL.22,26-32
Nevertheless, the use of MRD monitoring can be limited by
the cost of these techniques.
In our study, we used a relatively low-cost FC method,
based on a limited panel of antibodies that was applicable in
87% of patients. This frequency of aberrant immuno-
phenotypes is similar to what has been reported in other
series.8,9,17,33-37
The FC method described in this study is also
affordable, rapid and easily performed in any cancer center
equipped with a basic single-laser flow cytometer, the FC-
equipment available in most Brazilian institutions. All these
features may facilitate the prospective validation of this
method in treatment protocols in developing countries.
Our study corroborates the theory that variations in
the occurrence of immature lymphoid precursors, which
resemble the phenotype of leukemic cells, may influence MRD
detection.26,34,38,39 Regenerative time points (weeks 24-30) were
characterized by a limited sensitivity for MRD assessment in
a high proportion of BCP-ALL cases due to the preponderance
of resurgent normal very immature precursor B-cells (data
not shown).
Kerst et al.21 reported that neither high percentages
nor the virtual absence of immature B-cells appeared to
influence flow cytometric estimates of MRD. In spite of this,
we found that options for investigating MRD may not depend
on leukemia itself, but also on time point-related factors such
as total count and developmental stage of normal cells. These
observations were also suggested by Dworzak et al.26 Hence,
strategic placement of assessments into non-regenerative
phases of treatment (when the numbers of immature B-cells
are too low or absent) may allow a more accurate determination
of MRD using few marker combinations that are sufficiently
broad to assess most patients as was proposed in a study
recently published by Coustan-Smith et al.40
For many years the material of choice to monitor MRD
in ALL has been BM. Repeated BM aspirates cause discomfort
and are a traumatic experience for children. Therefore, PB is
being used for MRD testing.41-45
Figure 1. Distribution of  MRD levels in BM and PB of patients with T-lineage ALL and B-lineage ALL during the remission induction therapy.
Values represent the percentage of residual disease determined by flow cytometry in paired BM and PB samples. Symbols indicate T-
lineage ALL (T) and B-lineage ALL (z)
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We found differences in the PB MRD of patients with T
and BCP-ALL. In T-ALL, cells expressing leukemia-associated
immunophenotypes were consistently present in the PB and
BM at remarkably similar levels. These findings and those of
other studies suggest that the PB can be used for MRD
investigation in T-ALL.44,45 However, in BCP-ALL, some
patients had no detectable cells with leukemia-associated
immunophenotypes in the PB despite their presence in the
BM. In addition, BM samples had higher MRD levels than
the PB. This result is consistent with other PB MRD
studies.41,42,44,45 In the study by Coustan-Smith et al.,44 the
presence of MRD in the PB of patients with BCP-ALL denoted
a more aggressive leukemia with an extremely high risk of
recurrence. Therefore, PB MRD assays may also be clinically
useful in BCP-ALL.
In conclusion, FC is a fast, applicable and relatively
inexpensive technique to detect MRD in children with ALL.
The method we herein describe must be prospectively
validated in the context of the treatment protocols used in
developing countries.
Resumo
A detecção de doença residual mínima (DRM) é um importante
fator prognóstico na leucemia linfóide aguda (LLA) infantil e forne-
ce informações sobre a resposta ao tratamento e o risco de recaída.
Entretanto, os altos custos das técnicas utilizadas limitam seu uso
nos países em desenvolvimento. Desta forma, realizamos um estu-
do prospectivo para avaliar a citometria de fluxo (CF), utilizando
três fluorescências e um painel limitado de anticorpos monoclonais,
como método de detecção de DRM em medula óssea (MO) e sangue
periférico (SP) de crianças com LLA. Amostras de MO e SP de 40
crianças portadoras de LLA foram analisadas nos dias (d)14 e d28
da indução e nas semanas 24-30 da terapia de manutenção. Foram
consideradas como DRM+ as amostras que apresentaram ≥ 0,01%
das células com o fenótipo aberrante (FA). Oitenta e sete por cento
dos pacientes apresentaram FA ao diagnóstico. No d14, 56% das
amostras de MO e 43% do SP apresentaram DRM. No d28, foi
detectada DRM em 45% e 31% das amostras de MO e SP, respec-
tivamente. A porcentagem de DRM na MO foi similar à do SP nos
casos de LLA-T, mas aproximadamente dez vezes maior na LLA de
precursor-B. Foi detectada DRM na MO de 44% e 39% dos paci-
entes que estavam remissão morfológica nos d14 e d28, respectiva-
mente. Não foi demonstrada associação significante entre a presen-
ça de DRM e sexo, idade, leucometria inicial e linhagem celular.
Esta técnica de detecção de DRM por CF é relativamente barata e
pode ser aplicada em centros com recursos limitados. Rev. bras.
hematol. hemoter. 2008;30(4):281-286.
Palavras-chave: Doença residual mínima; leucemia linfóide agu-
da; citometria de fluxo; criança; sangue periférico.
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